Mineralys Therapeutics, Inc. Share Price & Technical Analysis
MLYS · $29.85 (-1.26%)
Healthcare / Biotechnology
$29.85
-1.26%
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and…
Price chart
Seasonality
May has 4 positive and 0 negative years (last 4 years shown)
8% return in May, 7% avg return in past 3 year May month.
-24% return in 2026, 28% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -15% | -5% | -7% | -5% | 8% | – | – | – | – | – | – | – | -24% |
| 25 | -16% | -9% | 73% | -14% | 10% | -14% | 4% | 9% | 68% | 7% | 8% | -16% | 111% |
| 24 | 28% | 40% | -17% | -5% | 3% | -10% | 6% | 0% | -2% | 12% | -5% | -4% | 45% |
| 23 | – | -16% | -11% | -14% | 7% | 18% | -17% | -9% | -27% | -19% | -14% | 30% | -72% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Uptrend
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.40B
P/E ratio
—
52W high
$47.65
52W low
$12.59
Volume
7,86,960
Beta
0.48
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Mineralys Therapeutics, Inc. share price today?
- Mineralys Therapeutics, Inc. (MLYS) last traded around $29.85 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MLYS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MLYS. Download the app for real-time alerts.
- How can I analyze Mineralys Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.